Intervention: Tucatinib plus Trastuzumab Subcutaneous (SC)
Found 5 matching trials
Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer
PHASE2
Breast cancer (BC) is the most common neoplasm in the world. In Spain, one ...
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
PHASE2
The purpose of the study is to learn from the real world practice of prescr...
Status
Recruiting
Location
University of Alabama at Birmingham Comprehensive Cancer Center